AMR SVG Icons location

Aminocaproic Acid Injection, USP


  • “AP” Rated to Amicar®*1
  • Vial closure is not made with natural rubber latex

Receive Availability Emails

  Pack NDC# Strength Supplied As Shelf Pack Vial Opening Size Product Info Availability
Strength:

250 mg/mL

Supplied As:

20 mL
Multiple Dose Vial

NDC#: 0517-9120-25
0517-9120-25

250 mg/mL

20 mL
Multiple Dose Vial

25 20 mm In-Stock Shipping Weekly
  • Shelf Pack 25
  • Availability In-Stock Shipping Weekly

Wholesaler Numbers

  • ABC/SAP 10047558
  • Cardinal 3453685
  • McKesson 1124866
  • Morris & Dickson 469312

Case Information

  • Unit of Sale NDC 0517-9120-25
  • Order Size 25
  • Case Size 4
  • Case Per Tier 126
Strength:

250 mg/mL

Supplied As:

20 mL
Multiple Dose Vial

NDC#: 0517-9191-25
0517-9191-25

250 mg/mL

20 mL
Multiple Dose Vial

25 20 mm In-Stock Shipping Weekly
  • Shelf Pack 25
  • Availability In-Stock Shipping Weekly

NOVAPLUS

Wholesaler Numbers

  • ABC/SAP 10232214
  • Cardinal 5586169
  • McKesson 2584985
  • Morris & Dickson 818419

Case Information

  • Unit of Sale NDC 0517-9191-25
  • Order Size 25
  • Case Size 4
  • Case Per Tier 126

*Amicar® is a registered trademark of Clover Pharmaceuticals Corp.

1Approved Drug Products with Therapeutic Equivalence Evaluations.
https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=A&Appl_No=071192. Accessed September 27, 2018.

Contact Us

Request for Medical Information Request a Grant Investigator Initiated Study Request a Certificate of Analysis Expanded Access Policy
Please choose your preferred method of contact

By clicking Submit, you confirm that you accept our Privacy Policy and that you agree to your personal contact information being used to contact you and added to our database. If at any time you wish your personal information to be removed from the American Regent® database, please submit a message request to corpcommunications@americanregent.com.

For intravenous infusion after dilution.

INDICATIONS AND USAGE
Aminocaproic Acid Injection is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, fresh whole blood transfusions, fibrinogen infusions, and other emergency measures may be required.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process.

WARNINGS
Aminocaproic Acid Injection, USP contains benzyl alcohol as a preservative. The administration of medications containing benzyl alcohol as a preservative to premature neonates has been associated with a fatal "Gasping Syndrome".
Aminocaproic acid should not be used in hematuria of upper urinary tract origin, unless the possible benefits outweigh the risk.
Skeletal muscle weakness with necrosis of muscle fibers has been reported following prolonged administration. The possibility of cardiac muscle damage should be considered when skeletal myopathy occurs. One case of cardiac and hepatic lesions observed in man has been reported. The patient received 2 g of aminocaproic acid every 6 hours for a total dose of 26 g. Death was due to continued cerebrovascular hemorrhage.

PRECAUTIONS
General: Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The drug should NOT be administered without a definite diagnosis and/or laboratory finding indicative of hyperfibrinolysis (hyperplasminemia).
Rapid intravenous administration of the drug should be avoided since this may induce hypotension, bradycardia, and/or arrhythmia.
Thrombophlebitis, a possibility with all intravenous therapy, should be guarded against by strict attention to the proper insertion of the needle and the fixing of its position.
Epsilon-aminocaproic acid should not be administered with Factor IX Complex concentrates or Anti-Inhibitor Coagulant concentrates, as the risk of thrombosis may be increased.
Laboratory Tests: The use of aminocaproic acid should be accompanied by tests designed to determine the amount of fibrinolysis present.
Drug/Laboratory Test Interactions: Prolongation of the template bleeding time has been reported during continuous intravenous infusion of aminocaproic acid at dosages exceeding 24 g/day. Higher plasma concentrations of aminocaproic acid may occur in patients with severe renal failure.
Pregnancy: Pregnancy Category C. Aminocaproic acid should be given to a pregnant woman only if clearly needed.
Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when aminocaproic acid is administered to a nursing woman.
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Aminocaproic Acid Injection, USP contains benzyl alcohol as a preservative. Benzyl alcohol has been associated with a fatal "gasping syndrome" in neonates.

ADVERSE REACTIONS
The following adverse experiences have been reported:
General: Edema, headache, malaise.
Hypersensitivity Reactions: Allergic and anaphylactoid reactions, anaphylaxis.
Local Reactions: Injection site reactions, pain and necrosis.
Cardiovascular: Bradycardia, hypotension, peripheral ischemia, thrombosis.
Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting.
Hematologic: Agranulocytosis, coagulation disorder, leukopenia, thrombocytopenia.
Musculoskeletal: CPK increased, muscle weakness, myalgia, myopathy, myositis, rhabdomyolysis.
Neurologic: Confusion, convulsions, delirium, dizziness, hallucinations, intracranial hypertension, stroke, syncope.
Respiratory: Dyspnea, nasal congestion, pulmonary embolism.
Skin: Pruritus, rash.
Special Senses: Tinnitus, vision decreased, watery eyes.
Urogenital: BUN increased, renal failure. There have been some reports of dry ejaculation during the period of aminocaproic acid treatment reported to date in hemophilia patients.

OVERDOSAGE
Effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. One patient with a history of brain tumor and seizures experienced seizures after receiving an 8 gram bolus injection of aminocaproic acid. Aminocaproic acid is removed by hemodialysis and may be removed by peritoneal dialysis.

DOSAGE AND ADMINISTRATION
RAPID INJECTION OF AMINOCAPROIC ACID INJECTION, USP UNDILUTED INTO A VEIN IS NOT RECOMMENDED.

For additional Safety Information, please see Full Prescribing Information.

You are encouraged to report Adverse Drug Events (ADEs) to American Regent, Inc. at 1.800.734.9236 or to the FDA by visiting www.fda.gov/MedWatch or calling 1.800.FDA.1088.

REF-0902  9/2018